CN Mobile Logo


Practice & Policy

Practice & Policy

Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.

Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.

The FDA announced the approval of trabectedin (Yondelis) for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or has metastasized.

One of the more difficult topics to discuss concerning the ethics of healthcare is distributive justice—the fair distribution of benefits, risks, and costs.

Palliative care should be provided with cancer care early in the course of illness for all patients with advanced disease, according to a new guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine.

Significantly more women are now aware of reconstructive surgery options after mastectomies for breast cancer, following coverage of Angelina Jolie’s mastectomies in 2013.

Rural cancer patients often face substantial barriers to receiving optimal treatment, including availability of cancer care providers, distance to services, lack of public transportation, financial barriers, and limited access to clinical trials. However, a number of promising approaches may address some of these challenges.


Subscribe to Practice & Policy on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.